March 2016, Vol 9, Seventh Annual Payers' Guide
Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas
Chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL) are common hematologic malignancies that represent a significant burden to patients and to the healthcare system. In light of the morbidity, mortality, and quality-of-life challenges associated with CLL and NHL, there is a marked need for additional therapeutic options for patients with these malignancies.
Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Toujeo (Insulin Glargine) U-300 Approved to Improve Glycemic Control in Adults with Type 1 and Type 2 Diabetes
Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
There is an urgent unmet need for more effective therapies in pancreatic cancer. The American Cancer Society estimated that approximately 49,000 new cases of pancreatic cancer will be diagnosed in the United States in 2015, and more than 40,500 people will die from this cancer.
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non–small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.
Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma
Finacia Foam (Azelaic Acid) the Newest Topical Treatment FDA Approved for the Treatment of Inflammatory Lesions of Rosacea
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor Approved for Postmenopausal Women with Metastatic Breast Cancer
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015.
American Health & Drug Benefits publishes a Payers' Guide to New FDA Approvals annually with the goal of providing payers and other healthcare stakeholders a comprehensive review of pharmaceuticals that were newly approved or that received important new indications by the US Food and Drug Administration (FDA) in the previous year.
Page 2 of 5
Results 11 - 20 of 43
Results 11 - 20 of 43